الفهرس 
MYELOID LEUKAEMIASOnly 14 pages are availabe for public view
 |  | from | 175 |  |  |
| | | from | 175 | | |
Abstract
Leukaemia is a disease resulting from the neoplastic proliferation of haemopoietic or lymphoid cells. It results from mutation of a single stem cell, the progeny of which form a clone of leukaemic cells. Usually there is a series of genetic alterations rather than a single event. Genetic events contributing to malignant transformation include inappropriate expression of oncogenes and loss of function of tumour suppressor genes.
AML is a group of neoplastic disorders characterized by an increase in the number of immature myeloid cells in the bone marrow with or without involvement of the peripheral blood. As a consequence, a bone marrow failure syndrome. Acute myeloid leukaemia (AML) can be divided into two subtypes: de novo, when it is not caused by chemotherapy or another preceding haematological condition, and secondary, when it is derived from such a condition.
Myeloproliferative neoplasms (MPNs) are clonal haematopoietic stem cell disorders characterized by proliferation of one or more of the myeloid lineages (granulocytic, erythroid, megakaryocytic and mast cell).The discovery of the Philadelphia chromosome, and the subsequent finding of the BCR-ABL chimeric gene, lead to a unique understanding of the biology of the disease that spurred the development of targeted therapy, as well as methods for the molecular monitoring of the disease. In combination, these pieces have been built into a therapeutic framework that is the envy of oncology.
The aim of this work is to study the expression of vascular endothelial growth factor in myeloid leukaemias and to correlate its level with other prognostic criteria.
This study was conducted on three groups, the first one (group A) were 15 newly diagnosed patients with Acute Myeloid Leukemia admitted at Hematology Oncology department of Ain Shams University Hospitals, the second group (group B) were 15 newly diagnosed patients with Chronic Myeloid Leukemia attending the Hematology Oncology clinic of Ain Shams University Hospitals, the patients were selected for the study on the basis of standard clinical, hematological and immunophenotypic criteria for diagnosis of acute and chronic myeloid leukemia and the third group (group C) were 10 age and sex - matched normal individuals acting as a control group.
In AML patients, there is statistically significant difference between patients and controls regarding VEGF expression level. Statistically higher VEGF level was found among patients with high level of LDH, BM blast (P=0.006, P<0.001, respectively). In addition, there is highly significant association between unfavourable cytogenetic risk factors and high VEGF level.
Also, in AML patients, as regard prognostic factors the mean sVEGF levels was higher in Patients with >50% blast in bone marrow and elevated LDH >480 U/L than in the group with <50% blast in bone marrow and normal LDH <480 U/L. also, mean sVEGF level was higher in AML patients with unfavorable cytogenetics than those with favorable cytogenetics.
In CML patients, there is statistically significant difference between patients and controls regarding VEGF expression level. Statistically higher VEGF level was found among elderly patients and those with high level of LDH (P=0.03, P=0.007 respectively).
However, no significant correlation between sVEGF and prognosis of CML patients as demonstrated by sokal score application.